Sun Pharma Acquires Organon for $11.75 Billion: India's Largest Pharma Deal

India-based pharmaceutical giant Sun Pharmaceutical Industries has agreed to acquire US drugmaker Organon for $11.75 billion. According to Reuters, this acquisition marks the largest deal ever in India's pharmaceutical sector. The agreement will significantly expand Sun Pharma's global presence. Organon is known for specializing in women's health and biosimilar drugs. Sun Pharma's move is seen as part of its strategy to diversify its portfolio and increase its share in the US market. Under the deal, Sun Pharma will purchase all of Organon's shares in cash. Analysts note that this merger will provide Sun Pharma with economies of scale and could accelerate R&D investments. Organon's strong product pipeline and advanced marketing network will enhance Sun Pharma's global competitiveness. The deal is subject to regulatory approvals and is expected to close in the first half of 2025. This strategic step by Sun Pharma once again highlights the growth potential of India's pharmaceutical sector on a global scale. The company aims to significantly increase its annual revenue and gain access to new markets through this acquisition. Organon's current management team is expected to be largely retained. This is not investment advice.